^
    Back
    Association details:
    Biomarker:EGFR amplification
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    HMBD-001 (HER3 antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2023
    Title:

    Combining Anti-HER3 Antibody, HMBD-001, with EGFR Inhibition and Chemotherapy may Improve Treatment Outcomes in SqNSCLC

    Published date:
    08/08/2023
    Excerpt:
    Blockade of HER3 using HMBD-001 robustly inhibits tumor growth in multiple in vivo pre-clinical models of sqNSCLC. In models with EGFR amplification, HMBD-001 in combination with cetuximab shows potent tumor growth inhibition (>90%).